Pharmacology of the new target-specific oral anticoagulants

Removal of Dabigatran by Hemodialysis

(2012) Don N. Chang et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Edoxaban

(2011) A. John Camm et al.   DRUGS

Drug and dietary interactions of warfarin and novel oral anticoagulants: an update

(2011) Edith Nutescu et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

(2010) Christian T. Ruff et al.   AMERICAN HEART JOURNAL

Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin

(2010) Wolfgang G. Eisert et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate

(2010) Joachim Stangier et al.   CLINICAL PHARMACOKINETICS

Drug and dietary interactions of the new and emerging oral anticoagulants

(2010) J. M. Walenga et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers

(2010) Koichiro Ogata et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers

(2010) Jeanne Mendell et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The frequency of prescription of P-glycoprotein-affecting drugs in atrial fibrillation

(2010) L. JUNGBAUER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development

(2010) Mike Ufer   THROMBOSIS AND HAEMOSTASIS

Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects

(2009) Joachim Stangier et al.   CLINICAL PHARMACOKINETICS

In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies

(2009) L. Wang et al.   DRUG METABOLISM AND DISPOSITION

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban: An oral direct inhibitor of factor Xa

(2008) M. P. Gulseth et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran Etexilate

(2008) Joachim Stangier   CLINICAL PHARMACOKINETICS

Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development

(2008) Bengt I Eriksson et al.   CLINICAL PHARMACOKINETICS

Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans

(2008) N. Raghavan et al.   DRUG METABOLISM AND DISPOSITION